Screener
Mirum Pharmaceuticals, Inc.
MIRMMirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of transformative therapies for rare and orphan diseases.
Earnings
Next report
Nov 3, 2026 (in 2 months)Revenue estimate$178.1M
EPS estimate-$0.53
Valuation & ratios
Segments
By product
Competitors
By market cap
By revenue growth
By net margin
Profile
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of transformative therapies for rare and orphan diseases. The company's primary value proposition lies in its portfolio of approved medicines and clinical-stage candidates targeting debilitating liver diseases and other rare conditions with high unmet medical needs.
Competitive position
Mirum is a specialized player in the rare liver disease market, leveraging orphan drug designations and licensed intellectual property to maintain a niche competitive stance.
GeographiesUnited States, Global
Customer segmentsRare disease patients, Specialist physicians, Hospitals
Business modelR&D-based drug development, Commercial pharmaceutical sales
SuppliersSole-source drug substance manufacturers, Contract manufacturing organizations (CMOs), Intellectual property licensors, Clinical research organizations (CROs)
CustomersSpecialty pharmacies, Drug distributors, Hospitals and clinics, Third-party payers
CountryUnited States of America
Listed2019
Employees278.0
CEOChristopher Peetz
SectorHealthcare
IndustryBiotechnology
Websitemirumpharma.com
FilingsSEC EDGAR
FAQ
- What is Mirum Pharmaceuticals, Inc.'s market cap?
- Mirum Pharmaceuticals, Inc. (MIRM) has a market capitalization of $6.1B and trades on NASDAQ.
- What is Mirum Pharmaceuticals, Inc.'s revenue and profitability?
- Mirum Pharmaceuticals, Inc. generated $618.1M in trailing twelve-month revenue with a net loss of $860.2M, representing a net margin of -139.2%, with free cash flow of -$228.7M. The latest reported period is Q2 2026.
- Who are Mirum Pharmaceuticals, Inc.'s competitors?
- Mirum Pharmaceuticals, Inc.'s key competitors include Gilead Sciences, Alnylam Pharmaceuticals, Inc., Zevra Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Mirum Pharmaceuticals, Inc. partner with?
- Mirum Pharmaceuticals, Inc.'s notable partners include Takeda Pharmaceutical Company, Shire.
- Where is Mirum Pharmaceuticals, Inc. headquartered?
- Mirum Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 278 people. It has been publicly traded since 2019.
